349 related articles for article (PubMed ID: 16584829)
21. Placenta and myometrium--the two main sources of fibrinolytic components during pregnancy.
Uszyński M; Maciejewski K; Uszyński W; Kuczyński J
Gynecol Obstet Invest; 2001; 52(3):189-93. PubMed ID: 11598362
[TBL] [Abstract][Full Text] [Related]
22. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
23. [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer].
Gerstein ES; Shcherbakov AM; Kaz'min AI; Ognerubov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(2):165-9. PubMed ID: 12785198
[TBL] [Abstract][Full Text] [Related]
24. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
25. Evidence of increased oxidative stress and a change in the plasminogen activator inhibitor (PAI)-1 to PAI-2 ratio in early-onset but not late-onset preeclampsia.
Wikström AK; Nash P; Eriksson UJ; Olovsson MH
Am J Obstet Gynecol; 2009 Dec; 201(6):597.e1-8. PubMed ID: 19683696
[TBL] [Abstract][Full Text] [Related]
26. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms.
Lindholt JS; Jørgensen B; Shi GP; Henneberg EW
Eur J Vasc Endovasc Surg; 2003 Jun; 25(6):546-51. PubMed ID: 12787697
[TBL] [Abstract][Full Text] [Related]
27. Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury.
Yamanaka H; Obata K; Fukuoka T; Dai Y; Kobayashi K; Tokunaga A; Noguchi K
Neuroscience; 2005; 132(1):183-91. PubMed ID: 15780477
[TBL] [Abstract][Full Text] [Related]
28. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
29. Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.
Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
Agents Actions Suppl; 1992; 38 ( Pt 2)():342-9. PubMed ID: 1462840
[TBL] [Abstract][Full Text] [Related]
30. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
[TBL] [Abstract][Full Text] [Related]
31. [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia].
Gerstein ES; Gritsaenko EV; Shcherbakov ME; Shcherbakov AM; Ognerudov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(6):725-9. PubMed ID: 14976916
[TBL] [Abstract][Full Text] [Related]
32. Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1.
de Moerloose P; Mermillod N; Amiral J; Reber G
Thromb Haemost; 1998 Mar; 79(3):554-6. PubMed ID: 9531039
[TBL] [Abstract][Full Text] [Related]
33. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
[TBL] [Abstract][Full Text] [Related]
34. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
35. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Span PN; Witjes JA; Grebenchtchikov N; Geurts-Moespot A; Moonen PM; Aalders TW; Vriesema JL; Kiemeney LA; Schalken JA; Sweep FC
BJU Int; 2008 Jul; 102(2):177-82. PubMed ID: 18336603
[TBL] [Abstract][Full Text] [Related]
36. Relationship between maternal and cord blood hemostatic disturbances in preeclamptic pregnancies.
Catarino C; Rebelo I; Belo L; Rocha S; Castro EB; Patricio B; Quintanilha A; Santos-Silva A
Thromb Res; 2008; 123(2):219-24. PubMed ID: 18384840
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Caccamo DV; Keohane ME; McKeever PE
Mod Pathol; 1994 Jan; 7(1):99-104. PubMed ID: 8159659
[TBL] [Abstract][Full Text] [Related]
38. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
España F; Estellés A; Fernández PJ; Gilabert J; Sánchez-Cuenca J; Griffin JH
Thromb Haemost; 1993 Dec; 70(6):989-94. PubMed ID: 8165623
[TBL] [Abstract][Full Text] [Related]
39. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
40. [Changes in fibrinolysis-associated parameters in HELLP syndrome].
Kolben M; Lopens A; Schmitt M; Schneider KT; Graeff H
Geburtshilfe Frauenheilkd; 1994 May; 54(5):257-61. PubMed ID: 8050684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
